Editorial: ondansetron for patients with IBS-D and bowel-predominant symptoms-authors' reply

Aliment Pharmacol Ther. 2023 Jun;57(11):1337-1338. doi: 10.1111/apt.17496.

David Gunn^{1

2}, Alexander Ford^{3

4}, Amanda Farrin⁵, Robin Spiller^{1

2}

¹ NIHR Nottingham Digestive Diseases Biomedical Research Centre, University of Nottingham, Nottingham, UK.
² Nottingham Digestive Diseases Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK.
³ Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.
⁴ Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
⁵ Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.

No abstract available

Publication types